Bioventus Inc. Class A

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: −12.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.2% (SPY −0.4%, XLV +15.5%). 1 year: +51.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: BVS, SPY and XLV · as of 4 Nov 2026

2. 02

   8.9 days to cover short interest

   3.2M shares were sold short at the 15 Oct 2026 settlement, 4.7% of the 68.3M shares outstanding; covering them would take 8.9 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

3. 03

   Volume 2.6× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 1.3M shares was 2.6× the average of the 30 sessions before it (493.3K), as the price rose 4.3%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

4. 04

   Below its 50-day average, above its 200-day

   The 4 Nov 2026 close of $11.42 was 15.8% below its 50-day average ($13.57) and 4.2% above its 200-day average ($10.96). It has closed above the 200-day for 109 sessions, since 2 Jun 2026. The 50-day average crossed above the 200-day on 24 Dec 2025, 216 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

5. 05

   53% of the way up its 52-week range

   Closed at $11.42 on 4 Nov 2026: 28.1% below the 52-week high of $15.89 (5 Aug 2026) and 76.5% above the low of $6.47 (21 Nov 2025).

   Daily price bars, split-adjusted · as of 4 Nov 2026

At the 4 Nov 2026 close